Relmada Therapeutics(US:RLMD) Globenewswireยท2025-07-31 11:00Core Insights - Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system conditions [2] - The company plans to host a conference call and webcast on August 7, 2025, to discuss its financial results for Q2 2025 and recent business progress [1] Company Overview - Relmada's lead candidates, NDV-01 and sepranolone, are in mid-stage clinical development and aim to address significant unmet medical needs [2] - The company is advancing therapies that could transform treatment options in their targeted areas [2] Conference Call Details - The conference call is scheduled for August 7, 2025, at 4:30 PM ET [3] - Dial-in numbers for participants include 1-877-407-0792 for US and 1-201-689-8263 for international callers [3] - Webcast access will be available through the company's investor relations section [1][3]